Loading
A phase 3 trial testing QLS32015 in multiple myeloma, now recruiting.
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma is a phase 3 interventional study registered as NCT07138209, led by Qilu Pharmaceutical, and recruiting on the registry. Official title: A Phase 3 Randomised Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma. Planned enrolment is 228 participants (estimated). The study started in 2025-11-07 and primary completion is expected in 2027-12. No results have been posted on ClinicalTrials.gov.
Shares QLS32015, Qilu Pharmaceutical, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.